• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA: West Pharma recall of Vial2Bag fluid transfer systems is Class I

February 4, 2019 By Fink Densford

West Pharmaceutical Services - updated logo

The FDA recently labeled a select recall of West Pharmaceutical Services‘ (NYSE:WST) Vial2Bag fluid transfer systems over device functionality issues as Class I.

Class I designations, the FDA’s most severe, are used when there is a reasonable probability that product use could cause serious adverse health consequences of death.

The West Whiteland Township, Penn.-based company’s Vial2Bag fluid transfer systems are designed to connect a vial containing medication to an intravenous therapy bag to aid in mixing the medication with the IV fluids, according to an FDA release.

The company is recalling the devices due to a possibility that the systems may not adequately transfer concentrated medications from the vial to the IV bag prior to patient infusion.

“If inadequate transfer occurs, the drug delivered to the patient may have variable or unpredictable dosing, which means that a patient may be infused with an overdose or under-dose of medication, leading to life-threatening adverse health consequences,” the agency wrote in its posting.

The federal watchdog said that it has received 16 complaints of serious adverse health related consequences related to the use of the 13mm device with oxytocin in pregnant women during labor and delivery.

As the device can be used with a variety of different medications under different patient settings, the FDA said that all Vial2Bag systems are being recalled during an investigation of the issues.

The recall affects approximately 38.8 million Vial2Bag Direct Connect 13mm and 20mm and Vial2Bag devices with model numbers 6070104, 6070111 and 6070112 manufactured between February 9, 2016 and January 1, 2019 and distributed between March 15, 2016 and January 8, 2019, according to the release.

West Pharma began notifying customers of the issues late last month, and instructed them to immediately discontinue use and quarantine affected devices.

Last month, Drug Delivery Business News spoke to West global biologics biz VP Cindy Reiss-Clark on the drug delivery trends that stood out in 2018 and what could be coming during 2019.

Filed Under: Featured, Food & Drug Administration (FDA), Recalls Tagged With: West Pharmaceutical Services

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS